%0 Journal Article
%T Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
%A Marlana Orloff
%J Archive of "Oncolytic Virotherapy".
%D 2016
%R 10.2147/OV.S99532
%X On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US Food and Drug Administration approval for the treatment of melanoma in the skin and lymph nodes. Its approval has added yet another therapeutic option to the growing list of effective therapies for melanoma. Though the Phase III OPTiM trial has demonstrated its efficacy as a single agent, the target patient population remains narrow. With numerous effective and tolerable treatments available for unresectable and metastatic melanoma, intralesional therapies such as T-VEC are still finding their niche. T-VEC is now widely accepted as option for treatment; however, its combination with various other agents in an effort to expand its use and synergize with other interventions is still being explored. This article will review the pre-clinical and clinical work that eventually led to the Food and Drug Administration approval of this first-in-class agent, as well as address concerns about clinical application and ongoing research
%K T-VEC
%K talimogene laherparepvec intralesional
%K melanoma
%K oncolytic virus
%K virotherapy
%K immunotherapy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063497/